Syros price target lowered to $14 from $18 at Alliance Global Partners » 12:1903/0503/05/21
Alliance Global Partners…
Alliance Global Partners analyst Matt Cross lowered the firm's price target on Syros Pharmaceuticals to $14 from $18 and keeps a Buy rating on the shares. The subsequent Phase 2 trial of SY-1425 pushes back the analyst's expected timeframe for a U.S. launch in acute myelogenous leukemia to 2026. The AML landscape is "rapidly shifting" and Syros will need to "remain nimble" as it looks to combine SY-1425 with other therapeutics in this setting, Cross tells investors in a research note.
Syros Pharmaceuticals reports Q4 EPS (62c), consensus (50c) » 07:3303/0403/04/21
Reports Q4 revenue $5.7M,…
Reports Q4 revenue $5.7M, consensus $2.7M. Cash, cash equivalents and marketable securities as of December 31, 2020 were $174M, as compared with $91.4M on December 31, 2019. "2021 promises to be a pivotal year for Syros," said Nancy Simonian, CEO of Syros. "We moved our lead program into our first registration-enabling study and continue to advance all three of our clinical-stage programs with the aim of setting new standards of care for targeted populations of patients with hematological malignancies and solid tumors. Following our recent financings, we are operating from a position of substantial strength, with capital to advance SY-1425, SY-2101 and SY-5609 through multiple expected data readouts while investing in our gene control platform to fuel our long-term pipeline. We are focused on executing with excellence as we accelerate toward our goal of bringing medicines to market that provide profound benefits for patients."
J.B. Hunt upgraded to Buy on 'robust' demand at BofA » 07:0803/0403/04/21
As previously reported,…
As previously reported, BofA analyst Ken Hoexter upgraded J.B. Hunt to Buy from Neutral with a price target of $171, up from $151, as part of his upgrade of a number of truckload and intermodal stocks. While he has lowered his Q1 estimates for the group to account for February's winter storms, he generally is lifting his 2021 and 2022 estimates to reflect improved pricing and demand. With inventory replenishment set to continue through the summer, and consumer demand remaining high, Hoexter sees truckload carriers being positioned to "capitalize on a robust 2021 demand environment," he tells investors.
J.B. Hunt upgraded to Buy from Neutral at BofA » 06:5803/0403/04/21
BofA analyst Ken Hoexter…
BofA analyst Ken Hoexter upgraded J.B. Hunt to Buy from Neutral with a price target of $171, up from $151.
#SocialStocks: Facebook resumes political ads, Twitter announces long-term goals » 15:0903/0303/03/21
FB, TWTR, NFLX, WMT, ORCL, SNAP
Netflix launches Fast Laughs feature for mobile devices » 12:5003/0303/03/21
Netflix said it is…
Netflix said it is launching a new Fast Laughs feature for mobile devices. "Fast Laughs offers a full-screen feed of funny clips from our big comedy catalog including films (Murder Mystery), series (Big Mouth), sitcoms (The Crew) and stand-up from comedians like Kevin Hart and Ali Wong," the company said. "You access the feed through your bottom navigation menu by clicking on the Fast Laughs tab. Clips will start playing - when one ends another begins, to keep the laughs coming." Fast Laughs is available now for iPhone users in select countries, and Netflix will be testing the feature on Android soon. Reference Link
Lithium Americas price target lowered to C$30.50 from C$31 at Canaccord » 11:5203/0303/03/21
Canaccord analyst Katie…
Canaccord analyst Katie Lachapelle lowered the firm's price target on Lithium Americas to C$30.50 from C$31 and keeps a Speculative Buy rating on the shares.
Bionano Genomics customer Praxis Genomics receives DEX Z-codes from Palmetto » 09:3003/0303/03/21
Bionano Genomics announced that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of laboratory developed tests based on Saphyr. The DEX Z-Code modifier is a unique 5-character alpha-numeric code associated with certain molecular diagnostics tests and is typically used by certain payers as an adjunct to non-specific CPT codes when no specific CPT code applies. The code, submitted on a claim along with a particular CPT code provides greater clarity to help payers and physicians understand which test is being ordered, performed and billed. The process removes the need for the provider to submit large amounts of additional information with every claim and can expedite claim payment. The assignment of DEX Z-codes to Praxis's menu of Saphyr-based LDTs is potentially a major step forward in the coding and eventual coverage of Saphyr-based tests. Praxis is the first CAP-accredited, CLIA-certified diagnostic lab in the United States to develop and offer commercially an LDT based on whole genome analysis with Saphyr. Praxis uses optical genome mapping as an alternative to traditional methods of chromosomal microarray and karyotyping, as they seek to improve the rate of clinical diagnosis for patients with genetic disease. The Z-codes allow for a path for Medicare coverage and private insurance reimbursement for OGM with Saphyr of patients with suspected genetic disease.
Perion Network price target raised to $31 after guidance hike at Lake Street » 09:0703/0303/03/21
Lake Street analyst Eric…
Lake Street analyst Eric Martinuzzi raised the firm's price target on Perion Network (PERI) to $31 from $30 and keeps a Buy rating on the shares after the company raised both its Q1 and 2021 guidance for revenue and AEBITDA ahead of its March 8 investor day meeting. Search advertising spending has remained healthy early in 2021 and one of the benefits of Perion's 2020 contract renewal with Microsoft (MSFT) was an increased ability to monetize the relationship, said Martinuzzi, who adds that Perion's "outperformance remains impressive."
The Genome Partnership to hold a virtual meeting » 04:5503/0303/03/21
NSTG, TWST, PACB, QGEN, TXG, CDXS, PKI, ILMN, RHHBY, BNGO
Advances in Genome…
Advances in Genome Biology & Technology: AGBT 2021 Virtual Meeting will be held on March 1-3. Webcast Link